Stonepine Capital Management LLC Sells 95,344 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Stonepine Capital Management LLC lowered its holdings in scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 12.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 683,530 shares of the company's stock after selling 95,344 shares during the period. scPharmaceuticals comprises 2.0% of Stonepine Capital Management LLC's portfolio, making the stock its 17th largest position. Stonepine Capital Management LLC owned 1.37% of scPharmaceuticals worth $2,420,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in SCPH. Legato Capital Management LLC acquired a new position in shares of scPharmaceuticals in the 4th quarter worth approximately $37,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of scPharmaceuticals during the 4th quarter worth approximately $38,000. ProShare Advisors LLC bought a new position in scPharmaceuticals during the 4th quarter worth $48,000. Price T Rowe Associates Inc. MD bought a new position in shares of scPharmaceuticals during the fourth quarter worth about $54,000. Finally, Wells Fargo & Company MN grew its position in scPharmaceuticals by 110.5% in the 4th quarter. Wells Fargo & Company MN now owns 18,407 shares of the company's stock worth $65,000 after purchasing an additional 9,663 shares during the last quarter. 89.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Maxim Group lowered their price target on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of scPharmaceuticals in a research report on Thursday, March 20th.

scPharmaceuticals Stock Down 2.0%

scPharmaceuticals stock traded down $0.07 during trading hours on Friday, hitting $3.44. The company had a trading volume of 127,017 shares, compared to its average volume of 367,535. The firm's fifty day moving average is $2.63 and its 200-day moving average is $3.15. The firm has a market capitalization of $181.60 million, a P/E ratio of -1.81 and a beta of 0.17. scPharmaceuticals Inc. has a fifty-two week low of $1.94 and a fifty-two week high of $5.65. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). The company had revenue of $11.75 million during the quarter, compared to analyst estimates of $11.63 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. On average, research analysts forecast that scPharmaceuticals Inc. will post -1.53 earnings per share for the current year.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.